[en] In their later stages low grade lymphoma are incurable. These lymphomas being radio-sensitive, a treatment of metabolic radioimmunotherapy, using monoclonal antibodies (anti-CD20) as the carrier has been developed. The aim of this treatment is to use these antibodies to target radiation to tumor tissues while limiting toxicity to normal cells. Ibritumomab tiuxetan (Zevalin) is currently prescribed for patients with relapsed or refractory low-grade follicular lymphoma after rituximab treatment. This outpatient treatment has a high level of overall response rate including complete response and that for a long period. The side effects are essentially hematological and reversible. In the near future many more indications should become apparent and Zevalin should become an important tool in the B-cell lymphoma (low and high grade).
Disciplines :
Oncology
Author, co-author :
Witvrouw, Nancy ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire
De Prijck, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Hustinx, Roland ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire
Language :
French
Title :
Indications cliniques de la radiotherapie metabolique dans les lymphomes
Alternative titles :
[en] Clinical indications of radioimmunotherapy in lymphoma
* Bodet CSP, Oudoux A. La radioimmunothérapie en clinique. Médecine Nucléaire 2008;32:254-7.
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas : Clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol 1998;16:2780-95.
DeNardo GU Sysko VV, DeNardo SJ. Cure of incurable lymphoma. Int J Radiat Oncol Biol Phys 2006;66(Suppl. 2):S46-56.
Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radtoimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793-803.
Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma : Combined data from 4 clinical trials. J Nucl Med 2003;44:465-74.
Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005;16:786-92.
Zevalin Sumary of product characteristics(SmPC), EMEA 2004.
Goldenberg DM, Sharkey RM. Radioimmunotherapy of non-Hodgkin's lymphoma revisited. J Nucl Med 2005;46:383-4.
* Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 2003;21:1263-70.
Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrtum-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
* Triby C, Carrier P, Peyrade F, et al. Quelques perspectives concernant le traitement des lymphomes par Zevalin à partir de l'évaluation de l'expérience niçoise. Médecine Nucléaire 2008;32:85-95.
Zinzani PL, Tani M, Fanti S, Stefoni V, et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 2008;112:856-62.
Shimoni A, Zwas ST, Oksman Y, et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007;35:534-40.